Immunology:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}
      • Hit Back Against Crohns Disease with RINVOQ

      Unveiling the Future of Rinvoq in CD

      This on-demand video is a live recorded webinar held in December 2023, where leading experts in the field discussed the latest reimbursement updates for Rinvoq in CD, as well as important topics such as patient selection, efficacy and safety considerations, and practical patient care guidance.

      Chapters

      Speakers

      Assoc. Professor Gregory Moore

      MBBS (Hons) PhD FRACP
      Consultant Gastroenterologist, Head of IBD, Monash Medical Centre, Monash University

      Assoc. Professor Jakob Begun

      MD MPhil PhD FRACP
      Consultant Gastroenterologist, Mater Research Institute, University of QLD

      Dr Lena Thin

      MClinRes MBBS FRACP
      Consultant Gastroenterologist, Fiona Stanley Hospital, University of Western Australia

      References: 1. RINVOQ Product Information. 2. Australian Government. Department of Health and Aged Care. Australian Register of Therapeutic Goods (ARTG). Available at https://www.tga.gov.au/resources/artg. Accessed July 2023

      WARNING: Based on the results from a post-marketing safety study of another JAK inhibitor, RINVOQ should only be used if no suitable treatment alternatives are available in patients:
      • With history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long time smokers).
      • With malignancy risk factors (e.g. current malignancy or history of malignancy).
      • Who are 65 years of age and older.

      Refer to Product Information.

      PBS Information

      RINVOQ: Authority required. Refer to PBS Schedule for full authority information.

      Please review the full Product Information (PI) before prescribing, available below.

      RINVOQ PI

      AU-ABBV-240009. August 2024